Navigation Links
Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
Date:6/1/2009

Move strengthens Kendle's position as a global clinical development partner to the biopharmaceutical industry

CINCINNATI, June 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the opening of offices in Kuala Lumpur, Malaysia; Bangkok, Thailand; and Manila, Philippines. The new operations provide Kendle's global biopharmaceutical customers with access to additional patient populations while strengthening the Company's position as a global clinical development partner. Kendle has been active in the Asia/Pacific region since 1998 and currently operates offices in Beijing, Hong Kong and Shanghai, China; New Delhi and Ahmedabad, India; Singapore; and Sydney and Melbourne, Australia.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Kendle is one of the few truly global providers offering comprehensive Phase I-IV solutions to meet the needs of the world's biopharmaceutical industry," said Candace Kendle, PharmD, Chairman and CEO. "Our expanded presence in the Asia/Pacific region enhances opportunities for patient access, creates efficiencies in the clinical development process and overall strengthens Kendle's ability to foster global strategic alliances with the leading companies in the biopharmaceutical industry."

Kendle's expansion in Asia/Pacific reflects the growing importance of the region to the global clinical research market. Recent research by the Tufts Center for the Study of Drug Development indicates that within the next three years, as much as 65 percent of all FDA-regulated clinical trials will be conducted outside th
'/>"/>

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Kendle Announces First Quarter 2009 Results
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
4. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
5. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
6. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
7. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
8. Kendle to Present at the 2008 Credit Suisse Health Care Conference
9. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
10. Kendle Named a Best Place to Work in Greater Cincinnati
11. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... LIBREVILLE, Gabon, December 2 ...Everyone,s Problem and Heritage" , Coinci...2-3 June 2010 the,Gabonese Republic is hosting an ...the issue of safeguarding biological resources in ...ent and state leaders, ministers,scientific exper...
(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte ...l oral JAK2 inhibitor, SB1518, at The American Soc...ion in New Orleans. ,, Data will be presented o...ation trial of SB1518 detailing its safety, tolera... profile in dose levels ranging from 100 to 600 mg...
(Date:12/2/2009)..., SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The w... are in turmoil and uncertainty is part of many,bu...rma industry has been,relatively immune to the eco...ation. , During the midst of the difficul...n & Johnson inaugurated an R&D center in S...
(Date:12/1/2009)...NCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall...day announced revenue guidance for the fourth quar...illion, as compared with $69 million for the fourt... results was the first of two installment payments...fourth quarter 2008 results was a one-time $1.8 mi...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...urogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutic...ng novel pain management therapies, today announce...7, 2009 at 4:30 p.m. ET (1:30 p.m. PT) to report r...rence call will be hosted by Anthony DiTonno, Pres...glieri, Chief Financial Officer. , , To particip...
...maceuticals, Inc. (Nasdaq: TRBN ) today announce...first quarter ended March 31, 2009, after the clos... conference call will take place May 7, 2009, at 2...ewscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , ...n Trubion,s website at http://investors.trubion...
...chTechnology, Inc. (ERT), (Nasdaq: ERES ), a lea...logy, ePRO and other services to the biopharmaceut...unced today results for the first quarter of 2009....refer to changes from the same period a year ago. ... , Quarterly net revenue was $23.8 million ...
Other Biology Technology:NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results 2NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results 3Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call 2ERT Reports First Quarter 2009 Results 2ERT Reports First Quarter 2009 Results 3ERT Reports First Quarter 2009 Results 4ERT Reports First Quarter 2009 Results 5ERT Reports First Quarter 2009 Results 6ERT Reports First Quarter 2009 Results 7ERT Reports First Quarter 2009 Results 8ERT Reports First Quarter 2009 Results 9
(Date:12/1/2009)...Particularly in Alzheimer,s disease, nerve cell de...w therapeutic options may possibly be derived from...m. These findings have been published in the curre...nce . Until only a few years ago, neurogenesis th...d to be impossible in the adult brain. The textboo...
(Date:12/1/2009)...COLUMBUS, Ohio Ohio State University cancer resea...t both kills brain-tumor cells and blocks the grow...shows that viruses designed to kill cancer cells ... aggressive brain tumors if they also carry a gene..., The protein, called vasculostatin, is normally ...
(Date:12/1/2009)...Yehezkel Ben-Ari, winner of the 2009 Inserm Grand ...d its commitment to paying tribute to outstanding,...s. By honouring talents, Inserm intends to,demons...ved in today,s biological, medical and,health res...nd women who carry out and,drive this research ea...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2Tumor-attacking virus strikes with 'one-two punch' 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Narconon Centers Educate Thousands During Red Ribbon Week 60796 1Narconon Centers Educate Thousands During Red Ribbon Week 60796 2Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 1Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 2Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 1Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 2Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 3Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 4Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 5Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 6
... Neuroscience and Ophthalmology at LSU Health Sci...paper identifying, for the first time, a specific ...once thought to be no more than a byproduct, in re...imer,s disease. The paper, An NF-kB-sensitive micr...mer,s disease and in stressed human brain cells, w...
...re and University of St Andrews has identified a k... into a close relative in Britain, showing how gen...or evolution. , The researchers unravelled the r...e relative of the common British weed Groundsel, t...an amazing piece of genetic detective work, to be ...
...covered in the open ocean may force scientists to ...ogen cycle through ocean ecosystems. A research te...es at the University of California, Santa Cruz, ch...ic material, even though researchers have not been...the newly described organism seems to be an atypic...
Other Biology News:LSUHSC research identifies key contributor to Alzheimer's disease process 2Mysterious microbe may play important role in ocean ecology 2Mysterious microbe may play important role in ocean ecology 3
Rat Leptin, Unconjugated from R&D Systems
Rat Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals
Polaroid B&W positive, 3 x 4 inch pack film, 20 exp from Hoefer, Inc.
Normal Goat Serum from Cayman Chemical
Biology Products: